FTD showed a broad spectrum of anticancer activities against various colon cancer cell lines, irrespective of KRAS or BRAF mutation status, with IC50 values ranging from single to low double‐digit micromolar concentrations (Fig. S3). This evidence concerns the gene KRAS and colonic neoplasm.